<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ANISTREPLASE (APSAC)</span><br/>(a-ni'strep-lase)<br/><span class="topboxtradename">Eminase<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">thrombolytic enzyme</span><br/><b>Prototype: </b>Alteplase<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>30 unit vial</p>
<h1><a name="action">Actions</a></h1>
<p>A derivative of plasminogen streptokinase activator complex (APSAC). Activation of anistreplase occurs with deacylation of
         the drug.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>The production of plasmin from plasminogen by deacylated anistreplase can take place in the bloodstream or within the thrombus,
         which is more efficient. Both processes may contribute to thrombolysis.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Management of acute MI in adults by lysis of thrombi obstructing coronary arteries and reduction of infarct size. Initiation
         of treatment occurs immediately after the onset of acute MI.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Active internal bleeding, history of CVA, recent (within 2 mo) intracranial or intraspinal surgery or trauma, intracranial
         neoplasms, uncontrolled hypertension; severe allergic reactions to either anistreplase or streptokinase. Safety in children
         not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category C), lactation, major surgery within preceding 10 d, cerebral vascular disease, recent GI or GU bleeding,
         recent trauma, hypertension, age &gt;75 y, hemorrhagic ophthalmic conditions, current use of oral anticoagulants.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute MI</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 30 U IV push over 25 min<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: Start drug as soon as possible following the onset of clinical symptoms of acute MI.
            			
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span>  Dilute each dose with 5 mL sterile water for injection. Slowly add diluent, rolling vial to mix; do not shake.  Do not further dilute reconstituted solution. Diluted solution may be clear to pale yellow. Do not administer if particulate matter is present. Discard reconstituted solution after 30 min if not used. 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span>  Inject over 25 min directly into vein or IV line through the most proximal port.  During administration, only essential handling or moving of the patient should be done. 
               </p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity (<span class="speceff-life">anaphylactic and anaphylactoid reactions</span> in CV: 
      				<span class="speceff-life">Hemorrhage</span>, <span class="speceff-common">reperfusion arrhythmias, hypotension</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> Immediate. <span class="typehead">Peak:</span> 45 min after end of injection. <span class="typehead">Duration:</span> 46 h. <span class="typehead">Metabolism:</span> Metabolized in plasma. <span class="typehead">Half-Life:</span> 105120 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Baseline and periodic aPTT, bleeding time, PT, INR, TT; also draw blood for Hct, Hgb, and platelet counts for baseline
            values in case of bleeding.
         </li>
<li>Monitor vital signs q15min for first 6 h, including BP, pulse, respirations, and temperature. Report promptly bradycardia
            and allergic reaction.
         </li>
<li>Monitor neurological status q30min for 6 h.</li>
<li>Monitor for bleeding q15min for the first hour of therapy, every 30 min for second to eighth hour, then every 8 h.</li>
<li>Protect patient from invasive procedures; IM injections are contraindicated. Also avoid potentially traumatic procedures during
            thrombolytic therapy to prevent bruising.
         </li>
<li>Report signs of bleeding: gum bleeding, epistaxis, hematoma, spontaneous ecchymoses, oozing at catheter site, increased pain
            from internal bleeding. Interrupt infusion until bleeding stops.
         </li>
<li>Select radial rather than femoral artery if a blood gas determination is needed because a pressure dressing can more easily
            be applied to it to control oozing. It may be necessary to apply pressure to puncture sites for as long as 30 min.
         </li>
<li>
            							Note: Patient is at risk for postthrombolytic bleeding for 24 d after intracoronary anistreplase treatment. Continue monitoring
            vital signs until anticoagulant control is attained.
            						
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report incidents of bleeding to nurse or doctor. Report blood in urine and bloody or tarry stools.</li>
<li>Continue bed rest during therapy to prevent bleeding.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>